The Same Molecule, Two Very Different Goals

One compound, several programs

Ketamine is unusual in that a single molecule sits behind several genuinely different clinical intentions. Low-dose intravenous infusions for treatment-resistant depression. Higher, psychedelic-range dosing paired with psychotherapy. Sublingual maintenance for durability. Each has its own dose curve, its own setting requirements, and its own definition of success.

Blending them is the most common failure in the sector. A clinic optimized for rapid symptom relief in a medical suite is not automatically equipped to hold a psychedelic-range session, and a practice built around therapy hours may not have the monitoring discipline for infusions.

What each program actually looks like

Symptom-relief protocols run a fixed series of sub-psychedelic infusions over two to three weeks, monitored, scored and titrated. The bar is a measurable, sustained drop on a validated scale.

Psychotherapy-paired protocols use fewer, higher-dose sessions inside a prepared setting, each bracketed by preparation and integration hours with the same clinician. The bar is behavioral: something changes in how you live afterward.

Optimization-oriented use — the growing, least-regulated end of the market — targets emotional flexibility, creative range and stuck patterns in people who are not clinically depressed. It deserves the strictest screening and the most honest labeling, because the evidence base is youngest here.

Integration is where the work happens

The infusion is the cheapest part of the value chain and the most heavily marketed. The window it opens lasts days, sometimes weeks, and the outcome is decided by what gets written into it.

Serious programs schedule integration before your first session, not after it. That means named clinician hours, a structure for those sessions, and a plan for the behaviors you intend to change. If a clinic sells you six infusions and hands you a follow-up phone number, you are buying pharmacology and paying for a program.

Screening, honestly

Ketamine is not appropriate for everyone. A history of psychosis, poorly controlled hypertension, certain cardiac conditions, active dissociative substance use and pregnancy all change the calculus. Bladder toxicity is a real risk at high cumulative exposure, which makes unlimited at-home maintenance a genuine concern rather than a convenience feature.

A clinic that screens hard is not gatekeeping. It is the clearest signal you have that they intend to still be practicing in five years.

How to choose

Decide which program you are actually buying, then find a clinic that is excellent at that one. Ask who is in the room, what dose range they work in and why, how integration is staffed, what their protocol is for a non-response, and how they keep maintenance from drifting into unmonitored use.

The molecule is the same. The program is everything.